Antagonistas de los receptores de la angiotensina II
作者： LM Lazo Alonso de Caso , E Menchén del Cerro , J Clapera Navarro
DOI:
关键词:
摘要: Los antagonistas de los receptores la angiotensina II son nuevos agentes terapeuticos que han demostrado una eficacia antihipertensiva similar a otros farmacos utilizados en actualidad con un perfil tolerancia y seguridad excelentes. No obstante, falta estudios suficientes largo plazo, algunas incognitas su mecanismo accion mayor coste economico impiden tengan lugar definitivo practica clinica
unirioja.es
fmc.es参考文章(39)
Mimran A, Ribstein J, Angiotensin receptor blockers: pharmacology and clinical significance. Journal of The American Society of Nephrology. ,vol. 10, pp. 273- 277 ,(1999)
Björn Dahlöf, Kjell Pennert, Lennart Hansson, Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. American Journal of Hypertension. ,vol. 5, pp. 95- 110 ,(1992) , 10.1093/AJH/5.2.95
Luigi Corea, Ondina Cardoni, Roberto Fogari, Pierfranco Innocenti, Carlo Porcellati, Michele Provvidenza, Susanne Meilenbrock, John Sullivan, Frédéric Bodin, Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine Clinical Pharmacology & Therapeutics. ,vol. 60, pp. 341- 346 ,(1996) , 10.1016/S0009-9236(96)90061-2
Chantal Csajka, Thierry Buclin, Hans R. Brunner, Jérôme Biollaz, Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clinical Pharmacokinectics. ,vol. 32, pp. 1- 29 ,(1997) , 10.2165/00003088-199732010-00001
Mordchai Ravid, Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients Annals of Internal Medicine. ,vol. 118, pp. 577- 581 ,(1993) , 10.7326/0003-4819-118-8-199304150-00001
Allan I. Goldberg, Mary C. Dunlay, Charles S. Sweet, Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension American Journal of Cardiology. ,vol. 75, pp. 793- 795 ,(1995) , 10.1016/S0002-9149(99)80413-5
Michael Weber, Guidelines for assessing outcomes of antihypertensive treatment. American Journal of Cardiology. ,vol. 84, pp. 2- 4 ,(1999) , 10.1016/S0002-9149(99)00402-6
Suzanne Oparil, Robert Guthrie, Andrew J Lewin, Thomas Marbury, Karen Reilly, Joseph Triscari, Jeffrey A Witcher, An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan Clinical Therapeutics. ,vol. 20, pp. 398- 409 ,(1998) , 10.1016/S0149-2918(98)80051-9
Peter Gæde, Pernille Vedel, Hans-Henrik Parving, Oluf Pedersen, Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study The Lancet. ,vol. 353, pp. 617- 622 ,(1999) , 10.1016/S0140-6736(98)07368-1
Juliana C.N. Chan, Julian A.J.H. Critchley, Brian Tomlinson, Thomas Y.K. Chan, Clive S. Cockram, Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. American Journal of Nephrology. ,vol. 17, pp. 72- 80 ,(1997) , 10.1159/000169075